Gene therapy for cardiovascular disease.
Cardiovascular gene therapy has progressed to the point where clinical trials are now underway, in particular, for peripheral and myocardial ischemia and for restenosis. The delivery vectors are now more sophisticated--targeted to deliver genes only to specific tissues, and with gene expression regulated by disease-inducible promoters--which contributes to improved safety.
Kozarsky
K F
KF
GlaxoSmithKline, King of Prussia, PA 19406, USA. Karen_F_Kozarsky@sbphrd.com
D000818:Animals; D001161:Arteriosclerosis / Q000235:genetics / Q000628:therapy; D002318:Cardiovascular Diseases / Q000235:genetics / Q000628:therapy*; D002986:Clinical Trials as Topic; D023903:Coronary Restenosis / Q000235:genetics / Q000628:therapy; D004195:Disease Models, Animal; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006333:Heart Failure / Q000235:genetics / Q000628:therapy; D006801:Humans; D006949:Hyperlipidemias / Q000235:genetics / Q000628:therapy; D018919:Neovascularization, Physiologic; D020521:Stroke / Q000235:genetics / Q000628:therapy; D013997:Time Factors